Clinical Trial Update: Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma [Phase 2]

View source ↗

Summary

Phase 2a study of CAN-2409 with standard radiation therapy in malignant glioma (including glioblastoma multiforme) has completed; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• High-grade Glioma
• Malignant Glioma

Drugs mentioned

• CAN-2409

Snippet

Sponsor: Candel Therapeutics, Inc. | Conditions: Malignant Glioma, Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2024-04-03